Neurotech International Ltd has released a press release.
NTI initiates First Clinical Site for Phase 3 ASD Trial
Earlier from Neurotech International
- Appendix 4D & Half Year Report
- Positive 90-day GLP toxicology study results in non-rodents
- Approval received for NTI164 Phase 3 Clinical Study in ASD
- Quarterly Activities/Appendix 4C Cash Flow Report